Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
precision genetic medicinemedical
Precision genetic medicine uses a person’s specific DNA information to design treatments that target the biological cause of their illness rather than treating symptoms broadly. Think of it as a custom-tailored therapy that fits a patient’s genetic blueprint, which can improve effectiveness and reduce side effects. For investors, this approach can mean higher potential returns from premium-priced, narrowly targeted therapies but also greater regulatory, development and reimbursement risk tied to small patient groups and complex diagnostics.
Duchenne muscular dystrophymedical
A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.
central nervous systemmedical
The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.
cardiac diseasesmedical
Cardiac diseases are conditions that impair the heart’s ability to pump blood or maintain a steady rhythm, including blocked blood vessels, weakened heart muscle, valve problems, or irregular heartbeats. They matter to investors because treatments, medical devices and drugs for heart conditions represent large, often fast-changing markets; clinical trial results, regulatory decisions, or shifts in patient outcomes can quickly affect a healthcare company’s revenue and stock value — like a car’s engine determining the vehicle’s overall performance.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 12, 2026 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T.
The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
